Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Short term Debt (2017 - 2022)

Moleculin Biotech's Short term Debt history spans 6 years, with the latest figure at $86000.0 for Q4 2022.

  • Quarterly results put Short term Debt at $86000.0 for Q4 2022, down 21.1% from a year ago — trailing twelve months through Dec 2022 was $86000.0 (down 21.1% YoY), and the annual figure for FY2022 was $86000.0, down 21.1%.
  • Short term Debt for Q4 2022 was $86000.0 at Moleculin Biotech, down from $110000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $6.9 million in Q2 2019 to a low of $78000.0 in Q4 2020.
  • The 5-year median for Short term Debt is $117000.0 (2022), against an average of $1.2 million.
  • The sharpest move saw Short term Debt skyrocketed 1748.24% in 2019, then plummeted 98.55% in 2020.
  • Year by year, Short term Debt stood at $180000.0 in 2018, then tumbled by 45.0% to $99000.0 in 2019, then dropped by 21.21% to $78000.0 in 2020, then skyrocketed by 39.74% to $109000.0 in 2021, then dropped by 21.1% to $86000.0 in 2022.
  • According to Business Quant data, Short term Debt over the past three periods came in at $86000.0, $110000.0, and $95000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.